Actively Recruiting
Activated Charcoal Use in Chronic Kidney Disease Patients
Led by Mansoura University · Updated on 2025-08-08
40
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.
CONDITIONS
Official Title
Activated Charcoal Use in Chronic Kidney Disease Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult aged 6518 years with end-stage renal disease (ESRD)
- On stable maintenance hemodialysis three times weekly for at least 6 months
- Receiving phosphate binders according to kidney disease guidelines (KDIGO)
You will not qualify if you...
- Severely malnourished as diagnosed by a dietitian
- Receiving overnight dialysis treatment
- Having primary hyperparathyroidism or persistent parathyroid hormone levels greater than 800 pg/mL
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Urology and Nephrology Center
Al Mansurah, Please Select, Egypt
Actively Recruiting
Research Team
B
Basma M. Sayed Ahmed, M.Sc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here